31 results on '"Pennisi G."'
Search Results
2. OC.16.5: A MARKOV MODEL UNVEILING THE IMPACTOF RESMETIROMON THE NATURAL HISTORY OF MASLD PATIENTS WITH BASELINE SIGNIFICANT OR SEVERE LIVER FIBROSIS
3. OC.05.2: FIRST AND FURTHER LIVER DECOMPENSATION IN PATIENTS WITH METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE: WHAT CLINICAL IMPACT?
4. Presence and severity of esophageal varices drives portal hypertension-related complications in compensated advanced nonalcoholic fatty liver disease
5. Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease
6. OC.08.1 PROGRAMMED CELL DEATH 1 GENETIC VARIANT AND LIVER DAMAGE IN NONALCOHOLIC FATTY LIVER DISEASE
7. Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease and type 2 diabetes
8. AGILE-3 Score for the diagnosis of advanced fibrosis and for predicting liver-related events in nonalcoholic fatty liver disease
9. Pharmacological interventions effect on liver histology in nonalcoholic steatohepatitis: a network meta-analysis
10. Long-term therapy with intravenous human albumin increase survival in patients with decompensated cirrhosis and refractory ascites
11. First and further liver decompensation in patients with metabolic-dysfunction associated steatotic liver disease: what clinical impact?
12. Evaluation of ChatGPT as a counselling tool for Italian-speaking MASLD patients: assessment of accuracy, completeness and comprehensiveness
13. Identification of key predictors of significant weight loss in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: a multicentre study
14. Clinical outcomes of metabolic liver disease versus non-alcoholic fatty liver disease: a meta-analysis of observational studies
15. RESIST-NASH: a regional network for identification and referral of masld patients at risk for liver fibrosis
16. A Markov model unveiling the impact of Resmetirom on the natural history of MASLD patients with baseline significant or severe liver fibrosis
17. OC-06A cholestatic pattern predicts liver-related events in patients with nonalcoholic fatty liver disease
18. OC-10Liver-related and extrahepatic events occurrence in patients with nonalcoholic fatty liver disease: a competing risk analysis
19. GEMS, a GEnetic and Metabolic Staging predicting the outcome of non-alcoholic fatty liver disease
20. A cholestatic pattern predicts liver outcomes in patients with nonalcoholic fatty liver disease
21. Increased serum ferritin levels predict long-term mortality in patients with NAFLD
22. SIRT5 rs12216101 T>G variant is associated with fibrosis severity in patients with non-alcoholic fatty liver disease
23. NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease
24. T06.01.23 STEATOSIS AS A PREDICTIVE MARKER OF CARDIOVASCULAR ALTERATIONS IN A MEDITERRANEAN PRIMARY CARE COHORT
25. T06.01.15 IMPACT OF NON-ALCOHOLIC FATTY LIVER DISEASE ON CARDIOVASCULAR RISK IN A GENERAL POPULATION
26. PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with non-alcoholic fatty liver
27. A cholestatic pattern predicts liver outcomes in patients with nonalcoholic fatty liver disease
28. Liver stiffness measurement by fibroscan predicts the occurrence of liver-related events and death in patients with NAFLD-related compensated advanced chronic liver disease
29. PNPLA3 rs738409 C >G variant is associated with a higher risk of liver fibrosis progression assessed by FIB-4 and stiffness by fibroscan in patients with non-alcoholic fatty liver disease
30. FXR rs35724 G>C variant modulates cholesterol levels, carotid atherosclerosis and liver damage in non-alcoholic fatty liver
31. PNPLA3 rs738409 C>G variant predicts occurrence of liver-related events and death in non-alcoholic fatty liver
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.